Company Overview

Century Therapeutics, Inc. (NASDAQ: IPSC) is a U.S.-based biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for oncology and autoimmune diseases. The company operates within the biotechnology, cell therapy, and immuno-oncology industries, with a primary emphasis on creating allogeneic, or “off-the-shelf,” cellular medicines designed to overcome manufacturing and scalability limitations associated with autologous therapies. Century Therapeutics’ core technology platform combines gene editing, stem cell engineering, and differentiated immune effector cells, including natural killer (NK) cells and T cells, to develop standardized therapies intended for broad patient use.

The company’s principal revenue sources historically have included collaboration agreements, research funding, and licensing arrangements rather than commercial product sales, as its therapeutic candidates remain in clinical and preclinical development. Century Therapeutics has differentiated itself through its proprietary iPSC platform, which aims to enable scalable manufacturing, genetic engineering precision, and product consistency across treatment batches. Founded in 2018, the company emerged from scientific work associated with FUJIFILM Cellular Dynamics, Inc. and has evolved through strategic partnerships and internal platform development focused on next-generation cell therapy technologies.

Business Operations

Century Therapeutics organizes its operations around the development of engineered cell therapy candidates derived from renewable iPSC master cell lines. Its primary business activities involve research and development of oncology-focused therapies, including engineered NK cell and T-cell programs. The company’s platform integrates gene editing technologies, cell differentiation processes, and manufacturing capabilities intended to support repeatable production of immune cell therapies at commercial scale. Key pipeline programs have targeted hematologic malignancies and solid tumors through engineered cellular immunotherapy approaches.

The company operates primarily in the United States, with research, development, and manufacturing activities centered in Pennsylvania and associated biotechnology hubs. Century Therapeutics has maintained strategic collaborations with external pharmaceutical and biotechnology organizations, including partnerships related to cell engineering and therapeutic development. Historically, collaborations with entities such as Bristol Myers Squibb and relationships connected to FUJIFILM have supported platform expansion, research capabilities, and clinical development activities. The company’s operational assets include proprietary iPSC-derived cell lines, gene engineering technologies, and internal manufacturing expertise designed to support allogeneic cell therapy production.

Strategic Position & Investments

Century Therapeutics’ strategic direction has centered on advancing scalable allogeneic cell therapies capable of addressing limitations associated with patient-specific treatments, including manufacturing complexity, timing constraints, and cost. The company has invested substantially in iPSC-derived immune cell technologies, with development efforts focused on enhancing persistence, targeting specificity, and anti-tumor activity through engineered modifications. Its growth strategy has emphasized pipeline advancement, platform validation through clinical studies, and selective partnerships with larger pharmaceutical companies.

The company has also pursued investments in manufacturing and translational capabilities intended to support long-term commercialization potential. Strategic collaborations and licensing agreements have played an important role in funding development activities and expanding access to enabling technologies. Century Therapeutics remains active in emerging sectors including gene-edited immune cell therapy, next-generation NK cell therapeutics, and engineered T-cell platforms. Public filings and investor disclosures indicate ongoing prioritization of research efficiency, capital discipline, and clinical execution as the company advances its therapeutic candidates through development stages.

Geographic Footprint

Century Therapeutics is headquartered in Philadelphia, Pennsylvania, and its principal operations are concentrated in the United States biotechnology sector. The company’s activities primarily involve domestic research, clinical development, and corporate operations, although its strategic collaborations and investor base provide broader international exposure. Its platform technologies and development programs are positioned within the global immunotherapy and regenerative medicine markets, which include significant commercial opportunities across North America, Europe, and parts of Asia-Pacific.

While Century Therapeutics does not currently maintain the broad commercial infrastructure of a multinational pharmaceutical company, its partnerships and capital market presence provide international connectivity within the biotechnology ecosystem. Through affiliations involving FUJIFILM and global pharmaceutical collaborators, the company has participated in cross-border scientific and investment relationships that extend its influence beyond the domestic U.S. market.

Leadership & Governance

Century Therapeutics is led by executives with backgrounds in biotechnology, pharmaceutical development, cell therapy, and corporate strategy. Leadership has consistently emphasized scientific innovation, scalable manufacturing, and the development of standardized cellular medicines intended to improve patient accessibility and treatment consistency. The company operates under a governance structure typical of publicly traded biotechnology firms, with oversight from an independent board of directors and executive leadership team.

Key executives have included:

• Brent Pfeiffenberger – Chief Executive Officer
• Michael West, Ph.D. – Co-Founder
• Dan Dileo – Chief Financial Officer
• Christopher Cabell, M.D., MHS – Chief Medical Officer
• Matthew Kane, Ph.D. – Chief Scientific Officer

Company leadership has publicly emphasized the strategic importance of combining stem cell biology, gene editing, and immune cell engineering to establish a durable competitive position in the allogeneic cell therapy market. Public disclosures and corporate communications consistently describe a long-term focus on advancing clinical programs while maintaining platform flexibility for future therapeutic applications.